Phaseline

Companies › Sumitomo Pharma Switzerland

Sumitomo Pharma Switzerland: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Jul 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Relugolix
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 3Uterine FibroidsJul 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05862272RelugolixPhase 3Uterine FibroidsOncologyJul 2029

Targets

GNRHR (1)

Companies with the same targets

LG Chem JW Pharmaceutical Amgen AbbVie Pfizer TerSera Therapeutics Qilu Pharmaceutical Zhuhai Huahaikang Pharmaceutical Technology Kissei Pharmaceutical Changchun GeneScience Pharmaceutical

Companies built like this

Verity Pharmaceuticals SecuraBio Fidia Farmaceutici Eleison Pharmaceuticals Tianjin Hemay Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.